好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Ultra-Rapid Progressive Dementia: Characteristics of an Uncommon Neurological Disorder
Autoimmune Neurology
P2 - Poster Session 2 (2:45 PM-3:45 PM)
031

Determine the patient characteristics, clinical presentation, results of investigations, in patients with ultra-rapid progressive dementia (RPD).
The term RPD refers to dementia developing within one year, or complete incapacitation within two years of symptom onset. While most RPD patients exhibit subacute deterioration, a small subset develops dementia within 7 days. The causes and contributors to this ultra-rapid form remain poorly understood.

One-hundred and eighty-eight patients with RPD were prospectively enrolled in a study of RPD at Mayo Clinic (Jacksonville, Florida) and Washington University (Saint Louis, Missouri) from February 2016 to September 2023. Patients who developed persistent (≥1 month) dementia (global Clinical Dementia Rating® ≥1) within 7 days of the onset of first symptom were classified as ultra-RPD. Prospectively assessed patients were considered together with cases identified through systemic review of the extant literature to inform the patient characteristics, presenting symptoms and signs, results of common clinical tests, and causes of ultra-RPD.
Three patients in our prospective study of RPD had ultra-RPD (3/188, <2%): an 80-year-old female with right fornix acute infarction; a 92-year-old female with presumed strategic stroke, and a 71-year-old male with GABAB-receptor antibody-associated encephalitis presented with sudden amnesia. An additional 55 cases (with a median age of 55.0 years at symptoms onset [range: 18-97], 36% female) were reported in 47 publications attributed to vascular (41%), toxic/metabolic (24%), autoimmune/inflammatory (21%), and iatrogenic/structural (e.g., colloid cyst removal; 9%) causes. Brain MRI changes within Papez circuit structures were common in 52/57 (91%) patients with ultra-RPD, providing a unifying localization. Twelve patients (17%) had potentially treatment-responsive causes of ultra-RPD.
Patients with ultra-RPD are rarely encountered in clinical practice. The evaluation of patients with ultra-RPD should prioritize testing for potentially treatment-responsive vascular, toxic/metabolic, and autoimmune/inflammatory conditions that often disrupt neuroanatomical structures critical for memory formation and retrieval.
Authors/Disclosures
Yoav Piura, MD
PRESENTER 		Dr. Piura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Piura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck.
Tara Brigham (Mayo Clinic) No disclosure on file
Moain Abu Dabrh (Mayo Clinic Florida) No disclosure on file
Gregory S. Day, MD, MSc, FAAN (Mayo Clinic) Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has or had stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Amgen Pharmaceuticals. The institution of Dr. Day has received research support from AVID Radiopharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with 好色先生. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing 好色先生, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Ionis Pharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a 好色先生al Case Development + Presentation (video) with PeerDirect (P\S\L Group). Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development / Presentation (non-CME) with MJH Life Sciences (NeurologyLive). Dr. Day has a non-compensated relationship as a Clinical Director with Anti-NMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.